

Key Investor Information

This document provides you with key investor information about this fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this fund. You are advised to read it so you can make an informed decision about whether to invest. Unless otherwise defined in this document, all words and expressions defined in the Company's current Prospectus shall have the same meaning herein.

New Capital Healthcare Disruptors Fund (the "Fund"), a sub-fund of New Capital UCITS Fund Plc (the "Company")

New Capital Healthcare Disruptors Fund USD N Acc. (the "Share Class") – ISIN: IE00BKY80M12
The management company of the Fund is KBA Consulting Management Limited (the "Manager")

Objective and Investment Policy

Objective: The Fund's objective is to achieve capital appreciation through investment in a portfolio of equity securities.

Policy: The Fund will invest in equities issued by US companies listed or traded on Recognised Markets in the United States such as the NASDAQ, the New York Stock Exchange, the American Stock Exchange, the Chicago Mercantile Exchange and the Chicago Board of Trade across all market capitalisations. The Fund seeks to invest in companies that have the potential to change or entirely displace large segments of the healthcare economy. These investments entail innovative technologies that are driving the obsolescence of legacy products and practices.

The Fund may invest up to a maximum of 20% of the Net Asset Value in non-US companies including up to 10% of its assets in securities of emerging market issuers. These investments are generally made in American Depositary Receipts ("ADRs"), which are depositary receipts for foreign securities denominated in US dollars and traded on US securities markets or available through a US broker or dealer.

The Fund may invest in open-ended and closed-ended collective investment schemes provided such investments are eligible for investment by UCITS and such investments will not exceed in aggregate 10% of the Net Asset Value of the Fund.

The Fund will not invest in financial derivative instruments ("FDIs") for investment purposes. However, the Fund

may use forward foreign currency exchange contracts for hedging purposes.

Net income distributions for all 'Inc' share classes will be made on a bi-annual basis. 'Acc' share classes accumulate all net income.

Benchmark: The Fund's benchmark is the MSCI World Health Care Index. The Fund is actively managed and as such does not seek to replicate the Benchmark, but instead may differ from the Benchmark in order to achieve its objective. While certain of the Fund's securities may be components of the Benchmark, the Fund is not constrained by the Benchmark in the selection of investments and the Investment Manager will use its discretion to invest in securities not included in the Benchmark in order to take advantage of specific investment opportunities.

Profile of typical investor: The Fund is suitable for investors seeking capital growth over a 5 to 10 year time horizon with a high level of volatility commensurate with United States equities.

Dealing: Shares in the Fund can be bought and sold daily (every Business Day of the Fund).

Further information: Please refer to the Prospectus for more detailed information.

Risk and Reward Profile



The Fund is in category 6 as it has a high level of volatility.

The risk indicator is based on the volatility of the Benchmark's performance over the last 5 years. The risk category shown is not guaranteed and may shift over time. Historical data may not be a reliable indicator for the future risk profile of the Fund. The lowest risk category does not mean a "risk-free investment".

The Fund is also subject to risks which are not included in the calculation of the risk-reward indicator:

Liquidity risk: The risk that assets may not be saleable immediately at a price consistent with that observed for valuation purposes.

Currency risk: Investors not investing in their local currency will additionally be exposed to the fluctuation of the exchange rate between their local currency and the currency class in which they are invested.

Hedging risk: The Fund utilises forward exchange rate contracts to minimise currency risk. Forward contracts do not precisely mirror movements in the market exchange rate which can result in differences in performance between share classes.

Investment risk: There is no guarantee that the Fund will achieve its objective. A capital loss of some or the entire amount invested may occur.

Geographic concentration risk: A fall in the US market may have a significant impact on the value of the Fund because it primarily invests in this market.

Further information: The Prospectus for this Fund gives you more details about all the risks for this Fund – see under "Practical Information" for how to obtain a copy.

Charges

The charges you pay are used to pay the costs of running the Fund, including the costs of marketing and distributing it. These charges reduce the potential growth of your investment.

One-off charges taken before or after you invest

Entry charge	5.00%
Exit charge	0.00%

Charges taken from the fund over a year

Ongoing charges	3.00%
-----------------	-------

Charges taken from the fund under certain specific conditions

Performance fee	0.00%
-----------------	-------

The entry and exit charges shown are maximum charges. In some cases, you might pay less. You can find this out from your financial adviser.

The ongoing charges figure is based on the actual annualised expenses for the year ending 31 December 2021. This figure may vary from year to year and it excludes portfolio transaction costs and any performance fees if applicable.

For more information about charges, please see the "Fees and Expenses" section of the Prospectus.

Past Performance

There is insufficient data to provide a useful indication of past performance to investors.

Practical Information

The depositary bank of the Fund is HSBC Continental Europe, Ireland.

The Net Asset Value of the Share Class is calculated in USD and is available on Bloomberg, Morningstar and Reuters.

The Fund is a sub-fund of the Company, an umbrella fund with segregated liability between sub-funds. You can find out more information about the umbrella fund in the Prospectus. The Prospectus and periodic reports are prepared in the name of the Company. Copies of the Prospectus and the latest annual and half-yearly report are available free of charge from www.newcapitalfunds.com.

Subject to the conditions set down in the Prospectus, you are entitled to switch from one share class to another, either in the Fund or in another sub-fund of the Company. Please refer to the Prospectus for further information on how to switch.

The Fund is subject to the tax laws and regulations of Ireland. Depending upon your country of residence, this might have an impact on your investment. For further details please consult your financial adviser.

This Key Investor Information Document is specific to the Share Class but is considered representative of other share classes of this Fund, namely:

USD A Acc. ISIN: IE00BKY80L05

Information relating to these share classes is available in the Prospectus.

Details of the up-to-date remuneration policy of the Manager (including a description of how remuneration and benefits are calculated and the identity of persons responsible for awarding the remuneration and benefits) are available on www.kbassociates.ie. A paper copy will be made available upon request and free of charge by the Manager.

The Manager may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the Prospectus for the Fund.

Country of origin of the collective investment scheme:

Ireland

Swiss Representative: CACEIS (Switzerland) SA, Route de Signy 35, CH-1260 Nyon

Paying Agent: EFG Bank SA, Geneva Branch, 24 Quai Du Seujet, CH-1211 Geneva 2, Switzerland

Location where copies of the Prospectus, Key Investor Information Documents, the Memorandum and Articles of Association, and the annual and half yearly reports may be obtained free of charge:

CACEIS (Switzerland) SA, Route de Signy 35, CH-1260 Nyon, Switzerland